These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 7579358

  • 21. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides.
    Ratajczak MZ, Hijiya N, Catani L, DeRiel K, Luger SM, McGlave P, Gewirtz AM.
    Blood; 1992 Apr 15; 79(8):1956-61. PubMed ID: 1562723
    [Abstract] [Full Text] [Related]

  • 22. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T, Szczylik C, Malaguarnera L, Calabretta B.
    Folia Histochem Cytobiol; 1991 Apr 15; 29(3):85-9. PubMed ID: 1794439
    [Abstract] [Full Text] [Related]

  • 23. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
    Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B.
    Proc Natl Acad Sci U S A; 1994 May 10; 91(10):4504-8. PubMed ID: 8183938
    [Abstract] [Full Text] [Related]

  • 24. An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism.
    Smetsers TF, Linders EH, van de Locht LT, de Witte TM, Mensink EJ.
    Br J Haematol; 1997 Feb 10; 96(2):377-81. PubMed ID: 9029029
    [Abstract] [Full Text] [Related]

  • 25. Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by BCR-ABL anti-sense oligodeoxynucleoside phosphorothioates.
    Maekawa T, Kimura S, Hirakawa K, Murakami A, Zon G, Abe T.
    Int J Cancer; 1995 Jul 04; 62(1):63-9. PubMed ID: 7601569
    [Abstract] [Full Text] [Related]

  • 26. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.
    Moore S, Haylock DN, Lévesque JP, McDiarmid LA, Samels LM, To LB, Simmons PJ, Hughes TP.
    Blood; 1998 Oct 01; 92(7):2461-70. PubMed ID: 9746786
    [Abstract] [Full Text] [Related]

  • 27. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
    Rapozzi V, Cogoi S, Xodo LE.
    Mol Cancer Ther; 2006 Jul 01; 5(7):1683-92. PubMed ID: 16891454
    [Abstract] [Full Text] [Related]

  • 28. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
    Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B.
    Science; 1991 Aug 02; 253(5019):562-5. PubMed ID: 1857987
    [Abstract] [Full Text] [Related]

  • 29. A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations.
    Chasty R, Whetton A, Lucas G.
    Leuk Res; 1996 May 02; 20(5):391-5. PubMed ID: 8683978
    [Abstract] [Full Text] [Related]

  • 30. Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.
    Käbisch A, Pérènyi L, Seay U, Lohmeyer J, Pralle H.
    Acta Haematol; 1994 May 02; 92(4):190-6. PubMed ID: 7701917
    [Abstract] [Full Text] [Related]

  • 31. 5-Fluorouracil-resistant CD34+ cell population from peripheral blood of CML patients contains BCR-ABL-negative progenitor cells.
    Jazwiec B, Mahon FX, Pigneux A, Pigeonnier V, Reiffers J.
    Exp Hematol; 1995 Dec 02; 23(14):1509-14. PubMed ID: 8542939
    [Abstract] [Full Text] [Related]

  • 32. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
    Broaddus WC, Chen ZJ, Prabhu SS, Loudon WG, Gillies GT, Phillips LL, Fillmore H.
    Neurosurgery; 1997 Oct 02; 41(4):908-15. PubMed ID: 9316053
    [Abstract] [Full Text] [Related]

  • 33. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.
    Blood; 2005 Apr 15; 105(8):3303-11. PubMed ID: 15626746
    [Abstract] [Full Text] [Related]

  • 34. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.
    Haririan M, Kaviani S, Soleimani M, Ghaemi SR, Delalat B, Atashi A.
    Hematology; 2012 Jan 15; 17(1):28-34. PubMed ID: 22549445
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G, Hochhaus A, Schultheis B, Hehlmann R.
    J Cancer Res Clin Oncol; 1998 Jan 15; 124(12):643-60. PubMed ID: 9879825
    [Abstract] [Full Text] [Related]

  • 40. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
    Dilloo D, Hanenberg H, Lion T, Burdach S.
    Leukemia; 1995 Mar 15; 9(3):419-24. PubMed ID: 7885040
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.